Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D

Maureen A. Mealy, Audra Boscoe, Jaime Caro, Michael Levy

Research output: Contribution to journalArticle

Abstract

Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life. Methods: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms. Results: Twenty-one patients (90% women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score. Conclusions: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.

Original languageEnglish (US)
Pages (from-to)129-134
Number of pages6
JournalInternational Journal of MS Care
Volume21
Issue number3
DOIs
StatePublished - May 1 2019

Fingerprint

Neuromyelitis Optica
Pain
Quality of Life
Anxiety
Depression
Low Vision
Hypesthesia
Blindness
Neurology
Self Care
Optic Nerve
Rare Diseases
Neurologic Manifestations
Paralysis
Autoimmune Diseases
Multiple Sclerosis
Spinal Cord
Urinary Bladder
Equipment and Supplies

ASJC Scopus subject areas

  • Clinical Neurology
  • Advanced and Specialized Nursing

Cite this

Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. / Mealy, Maureen A.; Boscoe, Audra; Caro, Jaime; Levy, Michael.

In: International Journal of MS Care, Vol. 21, No. 3, 01.05.2019, p. 129-134.

Research output: Contribution to journalArticle

Mealy, Maureen A. ; Boscoe, Audra ; Caro, Jaime ; Levy, Michael. / Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D. In: International Journal of MS Care. 2019 ; Vol. 21, No. 3. pp. 129-134.
@article{27b71d53da2640d0ae375f54f51b0a06,
title = "Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D",
abstract = "Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life. Methods: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms. Results: Twenty-one patients (90{\%} women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score. Conclusions: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.",
author = "Mealy, {Maureen A.} and Audra Boscoe and Jaime Caro and Michael Levy",
year = "2019",
month = "5",
day = "1",
doi = "10.7224/1537-2073.2017-076",
language = "English (US)",
volume = "21",
pages = "129--134",
journal = "International Journal of MS Care",
issn = "1537-2073",
publisher = "Consortium of Multiple Sclerosis Centers (CMSC)",
number = "3",

}

TY - JOUR

T1 - Assessment of patients with neuromyelitis optica spectrum disorder using the EQ-5D

AU - Mealy, Maureen A.

AU - Boscoe, Audra

AU - Caro, Jaime

AU - Levy, Michael

PY - 2019/5/1

Y1 - 2019/5/1

N2 - Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life. Methods: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms. Results: Twenty-one patients (90% women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score. Conclusions: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.

AB - Background: Neuromyelitis optica spectrum disorder (NMOSD) is a rare autoimmune disease characterized by unpredictable attacks of the optic nerves and spinal cord that cause neurologic deficits, including weakness, numbness, bowel/bladder dysfunction, and pain and reduced vision and can ultimately lead to blindness and paralysis. We assessed the effects of NMOSD on quality of life. Methods: Adult patients with NMOSD treated at a US academic neurology clinic completed the EQ-5D and several other measures of functional status and quality of life. The EQ-5D scores and correlations across measures were evaluated, and scores were compared with those of patients with multiple sclerosis and US norms. Results: Twenty-one patients (90% women; mean age, 42.8 years; mean disease duration, 8.2 years) were included. The mean EQ-5D score was 0.74. Most patients reported at least some problems with mobility, pain/discomfort, usual activities, and/or anxiety/depression. Greater proportions of patients reported moderate or severe problems with mobility and pain/discomfort than they did with self-care, usual activities, or anxiety/depression. In a multivariate model, only the Brief Pain Inventory was a significant independent predictor of overall EQ-5D score. Conclusions: Neuromyelitis optica spectrum disorder has a substantial effect on multiple domains of quality of life. Pain seems to be among the primary drivers of the EQ-5D scores in NMOSD.

UR - http://www.scopus.com/inward/record.url?scp=85065590318&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85065590318&partnerID=8YFLogxK

U2 - 10.7224/1537-2073.2017-076

DO - 10.7224/1537-2073.2017-076

M3 - Article

C2 - 31191178

AN - SCOPUS:85065590318

VL - 21

SP - 129

EP - 134

JO - International Journal of MS Care

JF - International Journal of MS Care

SN - 1537-2073

IS - 3

ER -